27 results about "Suppressed appetite" patented technology

A combination therapy including both intranasal and oral solid-form preparations is described. In combination, the intranasal and oral delivery pathways provided an enhancement in appetite suppression and associated weight loss in comparison to either intranasal or oral solid-form therapy alone. It was unexpected that the observed substantial increase and increase in rate of weight loss would be observed for the combination therapy, which on average provided a nearly 12% reduction in total body weight over the three-month trial.

The invention provides a satiety dietary fiber composition for inhibiting appetite as well as a preparation method and application thereof, and relates to the technical field of foods. The satiety dietary fiber composition disclosed by the invention is prepared from the following components in parts by weight: 7.5 to 21 parts of dietary fiber particles, 5 to 18 parts of citrus fiber, 0.1 to 0.4 part of folium mori extract, 0.05 to 0.4 part of matcha powder, 0.05 to 0.4 part of sophora flower bud powder and 0.05 to 0.4 part of konjaku flour, the preparation method comprises the following steps: mixing organic acid, water and sodium carboxymethyl cellulose, and concentrating at the temperature of 30-100 DEG C; and continuously drying at the temperature of 100-180 DEG C to obtain the dietary fiber particles. The composition obtained by combining the high-swelling dietary fiber particles and supplementing the citrus fibers, the mulberry leaf extract, the matcha powder, the sophora flower bud powder and the konjaku flour has the effects of delaying digestion time and remarkably reducing weight and fat.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

To provide anti-obesity agents to overcome defects of currently used anti-obesity agents, that is, as main types of the previously developed anti-obesity drugs, appetite suppressants acting on the central nervous system are drugs that control the action of neurotransmitters (for example, phentermine, mazindol, lorcaserin, fluoxetine and sibutramine) were mostly used, but the neurotransmitter modulators exert a wide range of effects on various physiological actions in addition to appetite suppression by numerous subtype receptors, so that the modulators are lacking in selectivity for each subtype and have a large disadvantage in that various side effects are accompanied in a case of long-term administration.SOLUTION: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.SELECTED DRAWING: None

Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate insulin secretion and suppress appetite by activating ectopic olfactory receptors. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes, and disorders, such as abnormal insulin secretion.

A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dronedarone hydrochloride in preparation of anti-obesity and anti-diabetes medicines. According to the invention, ob / ob mouse and db / db mouse models are used, and experiments find that dronedarone hydrochloride can significantly reduce the weight of obese and diabetic mice, inhibit appetite, reduce fat content and liver weight, improve pancreas islet function, reduce serum glucose level, and effectively alleviate obesity and diabetes diseases. The potential application of dronedarone hydrochloride in treatment of obesity and type II diabetes provides new possibility for clinical treatment, and dronedarone hydrochloride is expected to become a new medicine for treating obesity and type II diabetes.

Provided is use of leuconostoc mesenteroides and / or metabolites thereof in preparing a composition for reducing body fat, suppressing appetite, promoting the ketone body level or regulating fasting blood glucose, wherein the leuconostoc mesenteroides is leuconostoc mesenteroides subsp. mesenteroides with the preservation number of DSM34443.

Provided herein are methods of treating, preventing, or reducing one or more symptoms or conditions associated with metabolic dysfunction, such as obesity, in a subject in need thereof using a non-naturally occurring melanocortin analog. In some embodiments, the non-naturally occurring melanocortin analog is administered orally. In some embodiments, the method comprises suppressing appetite in a subject in need thereof using a non-naturally occurring melanocortin analog in accordance with the present technology.

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

Compositions and methods for inducing weight loss, fat loss, maintaining weight or fat loss, suppressing appetite, reducing calorie intake, reducing weight gain, decreasing feed efficiency, increasing metabolic inefficiency, increasing energy expenditure, increasing thermogenesis and / or resetting metabolic set are disclosed. The compositions have a therapeutically effective amount of a ketogenic supplement, e.g., a ketone diesters, such as R,S 1,3-butanediol diacetoacetate. Compositions of one or more beta-hydroxy butyrate, beta-hydroxybutyrate salt, and medium chain triglycerides are also disclosed.

Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate insulin secretion and suppress appetite by activating ectopic olfactory receptors. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes, and disorders, such as abnormal insulin secretion.

Provided herein are methods of treating, preventing, or reducing one or more symptoms or conditions associated with metabolic dysfunction, such as obesity, in a subject in need thereof using a non-naturally occurring melanocortin analog. In some embodiments, the non-naturally occurring melanocortin analog is administered orally. In some embodiments, the method comprises suppressing appetite in a subject in need thereof using a non-naturally occurring melanocortin analog in accordance with the present technology.

Disclosed herein are compounds and ligands, and compositions formed therewith, which modulate insulin secretion, suppress appetite, and reduce body mass by activating G-protein coupled receptors (GPCRs), such as ectopic olfactory receptors, and transient receptor potential (TRP) ion channels. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes and obesity.

The invention discloses a solution for promoting fat burning and inhibiting appetite and a preparation method thereof. Normal saline is treated through low-temperature plasma (CAP) to become activated normal saline; the activated normal saline contains a large amount of active oxygen and active nitrogen, and after the normal saline is injected into the body, the active ingredients of the normal saline can promote fat burning and inhibit appetite through various ways, so that the effects of reducing fat and losing weight are achieved. Compared with an existing weight-losing mode, the weight-losing composition is free of side effects, quite obvious in effect and short in period. The invention fills up the blank of research on fat burning promotion and appetite inhibition of the plasma activation liquid.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

This invention provides a weight-loss formulation for subjects, wherein the active ingredient of the weight-loss formulation is carrageenan. This invention also provides the application of the active ingredient composed of carrageenan in the preparation of the weight-loss formulation for subjects. This invention creatively uses carrageenan alone as an active ingredient for weight loss, achieving very good weight-loss effects. At 24h, 48h, 72h, and 96h after injection, body weight decreased by 9.97% (P<0.05), 10.24% (P<0.05), 11.19% (P<0.01), and 13.21% (P<0.01), respectively, showing a gradually increasing trend, rapid onset, and significant effect. The weight-loss effect is superior to the latest oral weight-loss drug, the small-molecule GLP-1R agonist orforglipron. Furthermore, carrageenan, as an active ingredient, can also suppress appetite, reduce defecation, and increase urination.

The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors. In one embodiment, the present invention provides a composition of semaglutide and a selective androgen receptor modulator (SARM) compound of Formula IX.

The invention relates to a decoloring material for a lens surface coating film in vision, scenery or food is black and white in human eyes by filtering a specific spectrum so as to inhibit appetite, and the decoloring material is suitable for the field of fat reduction and sugar control. Different from traditional glasses, the color is directly converted into black and white through spectrum filtering, food temptation is reduced, and the brightness and definition of scenery are not changed. Meanwhile, by combining blue light resistance and ultraviolet protection functions, blue light damage to an electronic screen is reduced, ultraviolet rays are blocked, and the anti-blue-light protective film is suitable for long-term use of electronic equipment or use in a strong light environment. In addition, the anti-fog function is introduced, it is ensured that the lens is not fogged in the high-temperature and high-humidity environment, and the sight line is kept clear.

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

In an embodiment, the present disclosure pertains to an organ-specific wireless optogenetic device. In some embodiments, the device includes an electronic circuit, such that the electronic circuit is configured to harvest and convert radio frequency (RF) energy into optical energy and a tether having a μLED, where the μLED illuminates targeted regions in the organ. In an additional embodiment, the present disclosure pertains to a method of treating obesity. In general, the method includes implanting an organ-specific wireless optogenetic device into a subject, activating an RF-power system to produce RF energy, harvesting, by the organ-specific wireless optogenetic device, the RF energy, converting, by the organ-specific wireless optogenetic device, the RF energy into optical energy, illuminating, by the μLED, targeted regions in the stomach of the subject, and stimulating nerve endings to thereby suppress appetite in the subject.

The invention provides a stropharia rugoso-annulata double-target glycopeptide weight-reducing agent and application thereof, and belongs to the technical field of glycopeptides. The glycopeptide is composed of a polypeptide and a sugar chain, the amino acid sequence of the polypeptide is shown as SEQ ID NO.1, the sugar chain is N-acetyl glucosamine, and the N-acetyl glucosamine is connected to a first serine hydroxyl group of the polypeptide through an alpha-glucosidic bond in an O-connection glycosylation mode. The glycopeptide disclosed by the invention can be combined with the leptin, stabilize the four-spiral-beam conformation of the leptin, delay the degradation of the leptin, enhance the binding effect of the leptin and a leptin receptor and activate a melanocortin-4 receptor, and has potential multi-path weight-losing effects of inhibiting appetite and promoting energy consumption.

In an embodiment, the present disclosure pertains to an organ-specific wireless optogenetic device. In some embodiments, the device includes an electronic circuit, such that the electronic circuit is configured to harvest and convert radio frequency (RF) energy into optical energy and a tether having a μLED, where the μLED illuminates targeted regions in the organ. In an additional embodiment, the present disclosure pertains to a method of treating obesity. In general, the method includes implanting an organ-specific wireless optogenetic device into a subject, activating an RF-power system to produce RF energy, harvesting, by the organ-specific wireless optogenetic device, the RF energy, converting, by the organ-specific wireless optogenetic device, the RF energy into optical energy, illuminating, by the μLED, targeted regions in the stomach of the subject, and stimulating nerve endings to thereby suppress appetite in the subject.